Abstract

In a search for new potential multitarget anti-HIV compounds from natural products, we have identified in Hypericum scruglii, an endemic and exclusive species of Sardinia (Italy), a potent plant lead. The phytochemical study of the hydroalcoholic extract obtained from its leaves led to the isolation of its most abundant secondary metabolites, belonging to different chemical classes. In particular, three phloroglucinols derivatives were identified, confirming their significance as chemotaxonomic markers of the Hypericum genus. Among them, the 3-(13-hydroxygeranyl)-1-(2'-methylbutanoyl)phloroglucinol was reported here for the first time. All six isolated compounds have been evaluated firstly for the inhibition of both Human Immunodeficiency Virus type 1 (HIV-1) Reverse Transcriptase (RT)-associated DNA Polymerase (RDDP) and Ribonuclease H (RNase H) activities, for the inhibition of HIV-1 integrase (IN) in biochemical assays, and also for their effect on viral replication. Among the isolated metabolites, three phloroglucinol derivatives and quercitrin were effective on both RT-associated RDDP and RNase H activities in biochemical assays. The same active compounds affected also HIV-1 IN strand transfer function, suggesting the involvement of the RNase H active site. Furthermore, phloroglucinols compounds, included the newly identified compound, were able to inhibit the HIV-1 replication in cell based assays.

Highlights

  • Natural products have played, and will continue to play, a key role in drug discovery

  • We investigated the ability of the main compounds isolated from leaves of Hypericum scruglii to inhibit both Human Immunodeficiency Virus type 1 (HIV-1) RNA-dependent DNA polymerase (RDDP) and Ribonuclease H (RNase H) activities in biochemical assays

  • Based on previous observations [53], a phytochemical study was undertaken in order to isolate the most abundant compounds in the hydroalcoholic extract obtained from leaves of H. scruglii (Fig 1)

Read more

Summary

Introduction

Will continue to play, a key role in drug discovery. Plant products represent, according to an assessment of FDA on the source of natural products, over one-quarter of all approved new molecular entities [2,3]. Plants should be further investigated because new compounds with original structures and novel modes of action are continuously required. Occurring compounds frequently inspire synthetic medicinal compounds, and they could be chemically modified, based upon their structural and biological properties [5,6,7,8]. Their structural modification allows increasing their efficacy and selectivity, improving physicochemical, biochemical and pharmacokinetic properties, removing or reducing side effects

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.